Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBLG FibroBiologics	$0.59 +2.5%	$0.68	$0.53 ▼ $4.41	$24.08M	-0.74	523,478 shs	308,224 shs
GTBP GT Biopharma	$1.68 -4.0%	$2.46	$1.68 ▼ $4.10	$5.73M	1.33	67,466 shs	38,889 shs
QTTB Q32 Bio	$1.81 +7.7%	$1.87	$1.35 ▼ $53.79	$20.49M	N/A	527,676 shs	167,752 shs
RANI Rani Therapeutics	$0.53 -0.6%	$0.53	$0.39 ▼ $3.75	$33.56M	-0.02	1.18 million shs	903,854 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBLG FibroBiologics	+3.62%	+3.51%	-8.66%	-30.87%	-68.59%
GTBP GT Biopharma	+0.54%	-1.16%	-21.55%	-20.12%	-20.12%
QTTB Q32 Bio	-6.15%	-15.15%	-36.84%	+1.82%	-95.32%
RANI Rani Therapeutics	+6.20%	-2.75%	-17.55%	-4.63%	-78.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBLG FibroBiologics	3.3504 of 5 stars	3.6	4.0	2.6	2.5	0.6
GTBP GT Biopharma	3.123 of 5 stars	3.8	4.0	3.8	0.0	0.6
QTTB Q32 Bio	1.9632 of 5 stars	3.1	2.0	2.1	1.7	0.6
RANI Rani Therapeutics	2.5432 of 5 stars	3.5	1.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBLG FibroBiologics	3.20	Buy	$13.00	2,106.38% Upside
GTBP GT Biopharma	3.50	Strong Buy	$11.00	554.76% Upside
QTTB Q32 Bio	2.25	Hold	$12.17	572.19% Upside
RANI Rani Therapeutics	3.00	Buy	$7.33	1,288.89% Upside

Current Analyst Ratings Breakdown

Latest GTBP, QTTB, FBLG, and RANI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $12.00
8/4/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/29/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
5/15/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.02 per share	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	($0.75) per share	N/A
QTTB Q32 Bio	$1.16M	19.04	N/A	N/A	($1.00) per share	-1.81
RANI Rani Therapeutics	$1.03M	32.40	N/A	N/A	($0.14) per share	-3.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBLG FibroBiologics	-$11.16M	-$0.36	N/A	N/A	N/A	N/A	-710.25%	-118.02%	N/A
GTBP GT Biopharma	-$13.16M	-$5.69	N/A	N/A	N/A	N/A	-1,033.08%	-223.20%	8/13/2025 (Estimated)
QTTB Q32 Bio	-$47.73M	-$4.30	N/A	N/A	N/A	N/A	-2,709.70%	-61.16%	N/A
RANI Rani Therapeutics	-$30.02M	-$0.91	N/A	N/A	N/A	N/A	-2,272.39%	-97.97%	N/A

Latest GTBP, QTTB, FBLG, and RANI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	QTTB Q32 Bio	-$1.14	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	GTBP GT Biopharma	-$0.68	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RANI Rani Therapeutics	-$0.19	-$0.18	+$0.01	-$0.18	N/A	N/A
8/6/2025	Q2 2025	QTTB Q32 Bio	-$1.14	-$0.78	+$0.36	-$0.78	N/A	N/A
7/31/2025	Q1 2025	FBLG FibroBiologics	-$0.11	-$0.12	-$0.01	-$0.12	N/A	N/A
5/15/2025	Q1 2025	GTBP GT Biopharma	-$0.64	-$0.76	-$0.12	-$0.33	N/A	N/A
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBLG FibroBiologics	N/A	0.93	0.93
GTBP GT Biopharma	N/A	0.73	0.73
QTTB Q32 Bio	1.68	5.06	5.06
RANI Rani Therapeutics	2.75	0.54	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBLG FibroBiologics	N/A
GTBP GT Biopharma	8.15%
QTTB Q32 Bio	31.32%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
FBLG FibroBiologics	20.00%
GTBP GT Biopharma	3.40%
QTTB Q32 Bio	40.00%
RANI Rani Therapeutics	45.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBLG FibroBiologics	10	41.89 million	33.51 million	N/A
GTBP GT Biopharma	8	3.27 million	3.16 million	No Data
QTTB Q32 Bio	39	12.20 million	7.32 million	N/A
RANI Rani Therapeutics	110	63.21 million	34.71 million	Optionable

GTBP, QTTB, FBLG, and RANI Headlines

Recent News About These Companies

Rani Therapeutics Reports Q2 2025 Financial Results

August 13 at 5:20 AM | msn.com

RANI: Second Quarter Financial Results

August 12 at 7:19 PM | finance.yahoo.com

Rani (RANI) Q2 Net Loss Improves 16%

August 9, 2025 | theglobeandmail.com

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

August 7, 2025 | globenewswire.com

Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance

July 18, 2025 | finance.yahoo.com

Rani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering Announcement

July 15, 2025 | msn.com

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

July 15, 2025 | globenewswire.com

Rani Therapeutics Shares Surge After ENDO 2025 Presentation Announcement

July 14, 2025 | msn.com

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating ...

July 14, 2025 | bakersfield.comB

Rani Therapeutics to Present Preclinical Data on RaniPill® Capsule at ENDO 2025 Conference

July 14, 2025 | quiverquant.comQ

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

July 14, 2025 | globenewswire.com

Genelux Appoints Groen as General Counsel From Rani Therapeutics

July 8, 2025 | news.bloomberglaw.comN

Rani Therapeutics announces annual meeting results

May 30, 2025 | investing.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

Rani Therapeutics management to meet virtually with Lake Street

April 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP, QTTB, FBLG, and RANI Company Descriptions

FibroBiologics NASDAQ:FBLG

$0.59 +0.01 (+2.51%)

Closing price 04:00 PM Eastern

Extended Trading

$0.60 +0.01 (+0.98%)

As of 07:48 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

GT Biopharma NASDAQ:GTBP

$1.69 -0.06 (-3.40%)

As of 04:00 PM Eastern

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Q32 Bio NASDAQ:QTTB

$1.81 +0.13 (+7.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 +0.03 (+1.66%)

As of 04:56 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Rani Therapeutics NASDAQ:RANI

$0.53 0.00 (-0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$0.54 +0.01 (+1.52%)

As of 07:16 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time